X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (581) 581
overactive bladder (519) 519
index medicus (470) 470
male (385) 385
female (353) 353
urology & nephrology (318) 318
antimuscarinics (298) 298
urinary bladder, overactive - drug therapy (284) 284
urinary incontinence (264) 264
muscarinic antagonists - therapeutic use (251) 251
aged (245) 245
pharmacology & pharmacy (244) 244
antimuscarinic (232) 232
middle aged (228) 228
animals (225) 225
efficacy (201) 201
tolterodine (199) 199
treatment outcome (184) 184
double-blind (171) 171
adult (170) 170
quality-of-life (145) 145
oxybutynin (141) 141
muscarinic antagonists - adverse effects (136) 136
bladder (126) 126
solifenacin (125) 125
quality of life (122) 122
muscarinic antagonists - administration & dosage (120) 120
aged, 80 and over (113) 113
incontinence (113) 113
tolerability (112) 112
muscarinic antagonists - pharmacology (111) 111
antimuscarinic agent solifenacin (110) 110
safety (106) 106
detrusor overactivity (104) 104
tolterodine tartrate (104) 104
care and treatment (103) 103
antimuscarinic agents (101) 101
rats (101) 101
drug therapy (97) 97
solifenacin succinate (96) 96
medicine & public health (95) 95
antimuscarinic agent (93) 93
urology (93) 93
urinary-tract symptoms (91) 91
symptoms (89) 89
urinary incontinence - drug therapy (88) 88
analysis (85) 85
mirabegron (83) 83
dose-response relationship, drug (82) 82
double-blind method (82) 82
benzhydryl compounds - therapeutic use (80) 80
urinary-incontinence (79) 79
antimuscarinic drugs (75) 75
medicine, general & internal (74) 74
trospium chloride (72) 72
drugs (68) 68
urinary bladder - drug effects (64) 64
urinary bladder, overactive - physiopathology (64) 64
women (64) 64
cresols - therapeutic use (63) 63
in vitro techniques (62) 62
placebo-controlled trial (61) 61
therapy (61) 61
clinical trials (60) 60
benign prostatic hyperplasia (59) 59
prospective studies (59) 59
cholinergic antagonists - therapeutic use (58) 58
drug therapy, combination (57) 57
benzhydryl compounds - adverse effects (56) 56
internal medicine (56) 56
pharmacokinetics (56) 56
time factors (56) 56
benzhydryl compounds - administration & dosage (54) 54
management (54) 54
obstetrics & gynecology (54) 54
receptors, muscarinic - drug effects (54) 54
controlled trial (53) 53
darifenacin (53) 53
urinary bladder (52) 52
muscarinic receptors (51) 51
randomized controlled trials as topic (51) 51
fesoterodine (50) 50
guinea pigs (49) 49
parasympatholytics - pharmacology (49) 49
phenylpropanolamine - therapeutic use (49) 49
urge incontinence (49) 49
young adult (49) 49
urinary-bladder (48) 48
anticholinergic (47) 47
muscle contraction - drug effects (47) 47
quinuclidines - therapeutic use (47) 47
review (47) 47
tetrahydroisoquinolines - therapeutic use (46) 46
overactive bladder syndrome (45) 45
persistence (44) 44
pharmacotherapy (44) 44
beta-adrenoceptor agonist (43) 43
pharmacology/toxicology (43) 43
placebo (43) 43
prevalence (43) 43
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1051) 1051
Japanese (24) 24
German (18) 18
Spanish (14) 14
French (10) 10
Portuguese (2) 2
Italian (1) 1
Polish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cochrane database of systematic reviews (Online), ISSN 1469-493X, 2006, Issue 4, p. CD003781
Journal Article
Age and Ageing, ISSN 0002-0729, 09/2015, Volume 44, Issue 5, pp. 745 - 755
Aim: we aimed to systematically review drugs to treat lower urinary tract symptoms (LUTS) regularly used in older persons to classify appropriate and... 
Effectiveness | Adrenergic β-3 agonists | Adrenergic α blockers | Older people | Phosphodiesterase 5 inhibitors | Antimuscarinics | Systematic review | 5α-reductase inhibitors | Tolerability | Elderly | Lower urinary tract symptoms | effectiveness | DARIFENACIN | adrenergic alpha blockers | POPULATION | phosphodiesterase 5 inhibitors | adrenergic beta-3 agonists | elderly | antimuscarinics | ANTIMUSCARINIC AGENTS | PREVALENCE | systematic review | TROSPIUM CHLORIDE | MULTIMORBIDITY | MEDICATION USE | GERIATRICS & GERONTOLOGY | OVERACTIVE BLADDER | INCONTINENCE | tolerability | 5 alpha-reductase inhibitors | older people | CENTRAL-NERVOUS-SYSTEM | lower urinary tract symptoms | Age Factors | Risk Assessment | Administration, Oral | Humans | Risk Factors | Lower Urinary Tract Symptoms - physiopathology | Treatment Outcome | Adrenergic alpha-Antagonists - administration & dosage | Consensus | Patient Selection | Muscarinic Antagonists - administration & dosage | Urological Agents - adverse effects | Delphi Technique | Lower Urinary Tract Symptoms - drug therapy | Lower Urinary Tract Symptoms - diagnosis | 5-alpha Reductase Inhibitors - administration & dosage | Aging | Urological Agents - administration & dosage | Aged | Drugs | Usage | Urologic diseases | Care and treatment | Diagnosis | Drug therapy | Health aspects | Clinical trials | Medical treatment | Urinary tract diseases | adrenergic α blockers | adrenergic β-3 agonists | Systematic Reviews
Journal Article
Journal Article
Cochrane database of systematic reviews (Online), ISSN 1469-493X, 2012, Volume 1, Issue 1, p. CD005429
Journal Article
Journal Article
Journal of Cardiovascular Pharmacology and Therapeutics, ISSN 1074-2484, 12/2008, Volume 13, Issue 4, pp. 241 - 251
Antimuscarinics, used commonly to treat overactive bladder, may differ in their potential to increase heart rate via effects on cardiac muscarinic M2... 
Heart rate | Antimuscarinic | Overactive bladder | Tolterodine | Darifenacin | OVERACTIVE BLADDER SYNDROME | POPULATION | heart rate | CARDIAC & CARDIOVASCULAR SYSTEMS | RATE-VARIABILITY | SELECTIVE RECEPTOR ANTAGONIST | URINARY-BLADDER | MUSCARINIC RECEPTORS | MEDIATE CONTRACTION | PREVALENCE | darifenacin | tolterodine | INCONTINENCE | antimuscarinic | CARDIOVASCULAR-DISEASE | PHARMACOLOGY & PHARMACY | overactive bladder | Prospective Studies | Age Factors | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Cresols - adverse effects | Pyrrolidines - adverse effects | Benzofurans - pharmacology | Male | Phenylpropanolamine - pharmacology | Phenylpropanolamine - adverse effects | Pyrrolidines - pharmacology | Dose-Response Relationship, Drug | Heart Rate - drug effects | Benzhydryl Compounds - adverse effects | Time Factors | Muscarinic Antagonists - pharmacology | Tolterodine Tartrate | Aged, 80 and over | Heart Rate - physiology | Female | Cresols - pharmacology | Xerostomia - chemically induced | Double-Blind Method | Electrocardiography - drug effects | Benzofurans - adverse effects | Constipation - chemically induced | Cross-Over Studies | Aged | Benzhydryl Compounds - pharmacology | Delayed-Action Preparations | Urinary incontinence | Care and treatment | Usage | Heart beat | Physiological aspects | Research | Health aspects | Index Medicus
Journal Article
Side Effects of Drugs Annual, ISSN 0378-6080, 2015, Volume 37, pp. 433 - 459
The Side Effects of Drugs Annuals is a series of volumes describing the adverse effects and adverse reactions of drugs. The series supplements the content of... 
Cisapride | Domperidone | Alosetron | Calcineurin inhibitors | Histamine-2 (H2) receptor antagonists | Antimuscarinic | Trimebutine | Rabeprazole | Vitamin B12 | Metoclopramide | Serotonin-4 (5-HT | Gastroesophogeal reflux disease | Chloride channel activators | Dopamine receptor antagonists | Neurokinin-1 (NK1) receptor antagonists | Vedolizumab | Methotrexate | Constipation | Droperidol | Naloxegol | Dexlansoprazole | Granisetron | Clostridium difficile | Linaclotide | Antispasmodic agents | Guanylate cyclase-C agonists | Fosaprepitant | Bosutinib | Anticonstipation | Erlotinib | receptor antagonists | Ranitidine | Antiemetics | Magnesium salts | Laxatives | Proton pump inhibitors | Netupitant | Azathioprine | Phosphates | Diarrheal | Prokinetic agents | Pneumonia | Serotonin-3 (5HT | Racecadotril | Nemonoxacin | Opioid antagonists | Thiopurines | Antidiarrheal | Adversereactions | Polyethylene glycol | Biologics | Sulfasalazine | Hypomagnesemia | Bismuth salts | Aminosalicylates | Aprepitant | Pharmacogenetics | Pantoprazole | Irritable bowel | Cimetidine | Crohn's disease | Prucalopride | Antimetabolites | Otilonium bromide | Palonosetron | Omeprazole | Famotidine | Antibiotics | Mesalazine | receptor agonists | Esomeprazole | Lubiprostone | Clopidogrel | Teduglutide | Rifaximin | Glucagon-like peptide-2 analogs | Mycophenolate mofetil | Antacids | Lansoprazole | Ondansetron | Sodium picosulphate | Steroids | Ulcerative colitis
Conference Proceeding
Journal Article
BIOLOGICAL & PHARMACEUTICAL BULLETIN, ISSN 0918-6158, 12/2019, Volume 42, Issue 12, pp. 1996 - 2001
We evaluated the effects of anticholinergic drugs principally used for the therapy of overactive bladder (OAB) on the activity of P-glycoprotein, an efflux... 
SYSTEM | CELLS | MECHANISM | SENSITIVE MEASUREMENT | ANTIMUSCARINIC TREATMENTS | RHODAMINE-123 | P-glycoprotein | IN-VITRO | PHARMACOKINETICS | DIGOXIN | PHARMACOLOGY & PHARMACY | anticholinergic drug | overactive bladder | MEDIATED TRANSPORT ACTIVITY
Journal Article
Current Neuropharmacology, ISSN 1570-159X, 05/2017, Volume 15, Issue 4, pp. 637 - 653
Journal Article